Τίτλος: IMI2-2016-10-08 Personalised medicine approaches in autism spectrum disorders
Πρόγραμμα: Horizon 2020
Τύπος πρόσκλησης: Joint Undertaking (JU)
Φορέας Διαχείρισης: Innovative Medicines Initiative (IMI)
Δράση: Innovative Medicines Initiative 2 (IMI2)
Call ID: IMI2-2016-10-08
Action Type: RIA – Research and Innovation Actions
Προθεσμία first stage: 28/3/2017 17:00 Brussels Time / 2nd stage Deadline: 14 September 2017 17:00:00 Brussels Time
Η “Innovative Medicines Initiative” (IMI) είναι η μεγαλύτερη Ευρωπαϊκή πρωτοβουλία σύμπραξης δημόσιου – ιδιωτικού τομέα με σκοπό να επιταχύνει την δημιουργία καλύτερων και ασφαλέστερων φαρμάκων.
Συνοπτικά για την Πρόσκληση
Autism Spectrum Disorders (ASD) are common and severe neurodevelopmental disorders characterised by deficits in social communication and repetitive and restricted behaviours (including sensory anomalies). It is estimated that approximately 1% of children and adults are affected by ASD world-wide; that is nearly 5.5 million patients in the European Union (EU).
Currently, no effective medical treatments for the core symptoms are available and prior drug trials have been largely unsuccessful. Over the past years, major progress in the understanding of the genetics of autism, the development of in vitro and genetic animal models, and identification of several neurobiological phenotypes have opened new avenues for the identification of aetiology-based treatment targets. However, these advances were accompanied by increasing recognition of a further hurdle; namely the profound phenotypic and genetic heterogeneity between patients. For example, approximately 70% of people with ASD have one or more comorbidities. Likewise, hundreds of risk genes have been identified, yet each explains only a small percentage of patients. Last but not least there is poor understanding and knowledge on how the condition and the needs of the patients change in the different stages of life (e.g. in children, versus adolescents, versus adults with ASD). This highlights the need to move beyond one-size-fits-all treatment approaches and to develop stratified approaches that are tailored to the specific needs and biological profiles of particular patient subgroups…